As per the terms of the agreement, OctoPlus will act as a process development and manufacturing partner for microsphere-based formulation for the Danish pharma firm.
OctoPlus is a provider of formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide.
OctoPlus’ Locteron is a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C.
The company licensed Locteron exclusively to Biolex in October 2008.
Locteron is being manufactured for Biolex by OctoPlus and has recently completed Phase IIb clinical studies with superior clinical data versus current treatment.
Â